1 – 15 of 35
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Uncovering causal clues in the development of second primary cancers
(
- Contribution to journal › Letter
- 2023
-
Mark
Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI) : a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study
(
- Contribution to journal › Article
-
Mark
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1) : final survival analysis of a randomised, controlled, phase 3 trial
(
- Contribution to journal › Article
- 2021
-
Mark
Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study
(
- Contribution to journal › Article
-
Mark
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): : initial results from an international prospective study
(
- Contribution to journal › Article
- 2019
-
Mark
Master protocols in clinical trials : a universal Swiss Army knife?
(
- Contribution to journal › Scientific review
-
Mark
Tomosynthesis in breast screening : great expectations?
(
- Contribution to journal › Article
- 2018
-
Mark
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer : meta-analysis of individual patient data from ten randomised trials
- Contribution to journal › Article
- 2016
-
Mark
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
(
- Contribution to journal › Article
-
Mark
Morcellation and risk of malignancy in presumed ovarian fibromas/fibrothecomas
(
- Contribution to journal › Debate/Note/Editorial
- 2015
-
Mark
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
(
- Contribution to journal › Article
-
Mark
Global cancer surgery: delivering safe, affordable, and timely cancer surgery
(
- Contribution to journal › Article
-
Mark
Towards "next-generation" prostate cancer screening.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Endometrial cancer and oral contraceptives : an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies
(
- Contribution to journal › Article
-
Mark
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302) : final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
(
- Contribution to journal › Article